EODData

NASDAQ, ALVO:

18 Sep 2025
LAST:

7.820

CHANGE:
 0.11
OPEN:
7.940
HIGH:
8.000
ASK:
0.000
VOLUME:
308.2K
CHG(%):
1.39
PREV:
7.930
LOW:
7.750
BID:
0.000
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
18 Sep 257.9408.0007.7507.820308.2K
17 Sep 257.9508.0207.8707.930223.2K
16 Sep 258.1508.1507.8607.960220K
15 Sep 258.0408.1207.9818.120167.8K
12 Sep 258.0508.0607.9508.030221.2K
11 Sep 258.0308.1508.0308.050207K
10 Sep 258.1108.1607.9508.030207.1K
09 Sep 258.0908.1508.0108.110277.7K
08 Sep 258.3808.4108.0458.160309.3K
05 Sep 258.1208.4058.0938.330448.2K

COMPANY PROFILE

Name:
About:Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Sector:Healthcare
Address:9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
Website:https://www.alvotech.com
CIK:0001898416
ISIN:LU2458332611
FIGI:BBG014MBMZY2

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

P/E Ratio:37.78
Price to Sales:4.81
EBITDA:74.85M
Shares:311.6M
Market Cap:2.437B

TECHNICAL INDICATORS

MA5:7.97
MA10:8.05
MA20:8.10
MA50:8.51
MA100:9.11
MA200:10.25
RSI14:40.80
WPR14:-100.00
MTM14:-0.25
ROC14:-0.03
ATR:0.21
Week High:8.15
Week Low:7.75
Month High:9.06
Month Low:7.75
Year High:13.70
Year Low:7.35
Volatility:56.60